Nelfa Totipotency Markers for Embryonic Stem Cell Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to identify markers of totipotency to achieve and maintain maximum cellular plasticity for efficient reprogramming and therapeutic applications, as current understanding of totipotent cells and reprogramming strategies is inadequate.
Innovation Solution
The method involves detecting the expression level of Nelfa in embryonic stem cells and correlating it with a reference sample to determine potency state, and using anti-Nelfa antigen binding proteins to select totipotent-like cells, as well as inducing totipotency through metabolic regulators, small molecules, chemicals, viruses, nucleic acids, or polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional reprogramming strategies are used to generate iPSCs, then pluripotent stem cells can be obtained, but the reprogramming efficiency is relatively low
Solution Approach 1:
The invention changes the parameter of cellular potency from pluripotency to totipotency by inducing expression of totipotent markers (such as DUX, ZSCAN4, MERVL) in ESCs or iPSCs. This parameter change enables maximum cellular plasticity and significantly improves reprogramming efficiency, resolving the contradiction between productivity and reliability in reprogramming strategies.
2Adaptability or versatility
If totipotent cells are used for regenerative medicine, then maximum cellular plasticity is achieved, but the methods to identify and induce totipotency are insufficient
Solution Approach 1:
The invention uses marker expression profiles as detectable indicators to identify totipotent cells. By monitoring the expression of specific totipotent markers (DUX, ZSCAN4, MERVL, etc.), researchers can detect and measure the potency state of cells, enabling reliable identification of totipotent cells for regenerative medicine applications.
3Reliability
If early cleavage-stage embryos are used as the only source of totipotent cells, then true totipotency is obtained, but the availability and ethical constraints are limited
Solution Approach 1:
The invention uses totipotent markers as intermediaries to identify and characterize cells with totipotent characteristics that can be derived from ESCs or iPSCs. These markers serve as mediators to bridge the gap between conventional pluripotent cell sources and authentic totipotent cells, enabling therapeutic applications without requiring early cleavage-stage embryos.
Solution Approach 2:
The invention performs preliminary induction of totipotent marker expression in ESCs or iPSCs before they are used for therapeutic applications. By pre-inducing the totipotent state through genetic or chemical means, the cells are prepared in advance to exhibit maximum cellular plasticity, expanding therapeutic options without needing to source cells from early embryos.
Data Source
AI summary
The present invention relates to methods of determining a potency state of an embryonic stem cell (ESC) in culture, comprising detecting the expression level of Negative Elongation Factor Complex Member A (Nelfa) in the ESC, and correlating the expression level of Nelfa with that of a reference sample to determine the potency state of the ESC. The present invention also provides methods of selecting totipotent-like ESCs from a population of ESCs in culture using an anti-Nelfa antigen binding protein, methods of inducing totipotency in an ESC in culture, methods of improving the reprogramming efficiency of a somatic cell into an induced pluripotent stem cell and methods of reprogramming a somatic cell into a totipotent stem cell by inducing Nelfa expression. Cells comprising an expression vector encoding Nelfa and kits for use in the methods of the invention are also provided.